DXCMDexcom

$84.10+11% 1Y

Is it growing?

Excellent

Growing: revenue growing +16% year on year, earnings up +75% year on year, and operating margin widening (+7.0 points).

3 good
Revenue trend+16% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +18% a year.

Earnings trend+75% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+7.0 points operating

Trailing-twelve-month operating margin, 22.9% now against 15.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 82% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is DXCM growing?

Dexcom has grown revenue 16% a year over three years and 18% a year over five, with earnings per share compounding at 43%.

+16%

Revenue growth, 3-year annual rate · Medical Devices median +12% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
+18%

Revenue growth, 5-year rate · +16% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
+43%

Earnings per share, 3-year rate · revenue +16% · earnings outgrew revenue: margins or the share count worked for shareholders

Years of annual history on file
17

Years of annual history on file · FY2009 to FY2025, as filed

Details›
Revenue FY2021
$2.45B
Revenue FY2022
$2.91B
Revenue FY2023
$3.62B
Revenue FY2024
$4.03B
Revenue FY2025
$4.66B

Annual income statements as filed with the SEC.